Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
XERAVA (ERAVACYCLINE DIHYDROCHLORIDE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
XERAVA
NDA
Get alerts
ERAVACYCLINE DIHYDROCHLORIDE | N211109 | TETRAPHASE PHARMACEUTICALS INC
2 strengths
4 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
Medicare D
Medicare B
Approvals
Label
Products
Patent Timeline
4 unique patents, 2 exclusivities by expiration date
All strengths
EQ 50MG BASE/VIAL
EQ 100MG BASE/VIAL
Active (4)
Today
Exclusivity
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
Today
8796245
Aug. 7, 2029
8906887
Aug. 27, 2032
10961190
Oct. 19, 2037
11578044
Oct. 19, 2037
NCE
Aug. 27, 2023
GAIN
Aug. 27, 2028
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 50MG BASE/VIAL
RLD
4 patents
2 exclusivities
▴
POWDER;INTRAVENOUS | Approved: Aug 27, 2018
Patents (4)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
8796245
Aug 7, 2029
—
—
—
U-2380
TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
—
8906887
Aug 27, 2032
—
—
Yes
—
—
10961190
Oct 19, 2037
—
Yes
—
—
—
11578044
Oct 19, 2037
—
Yes
—
—
—
Exclusivities (2)
Code
Date
Status
GAIN
Aug 27, 2028
Active
NCE
Aug 27, 2023
Expired
#002 — EQ 100MG BASE/VIAL
RLD
4 patents
2 exclusivities
▾
POWDER;INTRAVENOUS | Approved: Jun 3, 2020